Takotsubo cardiomyopathy is an acute cardiac syndrome characterized by transient systolic dysfunction of the left ventricle, sometimes associated with right ventricular involvement, that mimics an acute coronary syndrome (ACS) but is not explained by a coronary occlusion responsible for the clinical presentation. The term derives from the morphology assumed by the left ventricle in the classic variant, with basal hyperkinesia and apical ballooning, resembling the Japanese octopus trap called takotsubo. In clinical practice, the term “stress cardiomyopathy” is still used, but it is less precise, because not all cases are preceded by an evident emotional stressor and because many episodes are triggered by acute physical conditions, neurological diseases, medical procedures, septic states, respiratory failure, severe pain or catecholaminergic exposure.
The disease predominantly affects postmenopausal women, with a mean age around the seventh decade in international registries, but it can also occur in men, young people and patients hospitalized for acute non-cardiac diseases. Its frequency is probably underestimated, because the onset is initially managed as acute myocardial infarction (AMI), because some focal or basal forms are difficult to recognize and because in critically ill patients clinical attention may be absorbed by the precipitating disease. In contemporary registries, Takotsubo is no longer considered a trivially benign condition: ventricular function tends to recover, but during the acute phase heart failure, cardiogenic shock, arrhythmias, ventricular thrombosis, systemic embolism and death may occur. The central point of the disease is therefore the dissociation between the morphological reversibility of ventricular dysfunction and the possible clinical severity of the acute event.
Takotsubo cardiomyopathy does not recognize a single necessary and sufficient etiological cause, but represents the convergence of individual predisposition, acute trigger and disproportionate neurocardiac response. For this reason, it is more accurate to describe it as a syndrome of myocardial vulnerability to neurovegetative and catecholaminergic stress rather than as a simple “emotional” disease. In typical cases, the trigger precedes onset by a few hours or a few days, but it may remain unidentifiable even after careful history-taking. The absence of an evident trigger does not exclude the diagnosis, because a substantial proportion of patients in international registries have no recognizable precipitating event.
Definite triggering events include conditions capable of violently activating the sympathetic nervous system or increasing myocardial exposure to catecholamines. Emotional stressors include bereavement, intense fear, sudden conflict, assault, a serious medical diagnosis, financial loss, catastrophic events and, more rarely, intense positive emotions. Physical stressors are at least equally important and include subarachnoid hemorrhage, stroke, epileptic seizure, head trauma, severe pain, sepsis, pneumonia, respiratory failure, pulmonary embolism, surgery, anesthesia, asthma attack, exacerbation of chronic obstructive pulmonary disease, pancreatitis, fractures, burns, chemotherapy, withdrawal syndromes and exogenous administration of catecholamines. Pheochromocytoma deserves a special position, because it can produce a catecholaminergic storm clinically and morphologically indistinguishable from Takotsubo and is included in the InterTAK criteria as a possible trigger.
The main predisposing factors are female sex, postmenopausal age, neurological disorders, psychiatric disorders, previous Takotsubo episode, severe acute diseases, malignancies, systemic inflammatory diseases, reduced cardiovascular reserve and conditions that increase baseline sympathetic tone. Female predominance suggests a role for loss of estrogenic protection after menopause. Estrogens modulate sympathetic tone, endothelial function, nitric oxide bioavailability, microvascular response, inflammation and myocardial sensitivity to catecholamines. Their reduction may increase the vulnerability of the coronary microcirculation and cardiomyocytes to adrenergic stimuli, although it does not constitute a sufficient cause by itself.
The relationship with neurological diseases is particularly relevant because it documents the role of the brain-heart axis. Subarachnoid hemorrhage, ischemic stroke, epileptic seizures, head trauma and other lesions of the central nervous system can induce massive sympathetic discharge through limbic, hypothalamic and brainstem structures that regulate autonomic tone. Neuroimaging studies have suggested alterations in connectivity between areas involved in emotional response, autonomic control and cardiovascular modulation. This observation explains why, in some patients, Takotsubo is a cardiac manifestation of primary neurovegetative dysregulation rather than the direct consequence of coronary artery disease.
The most widely accepted pathogenetic mechanism is acute catecholaminergic toxicity. High concentrations of adrenaline, noradrenaline and dopamine may cause overstimulation of cardiac adrenergic receptors, increased intracellular calcium, mitochondrial dysfunction, oxidative stress, altered energy metabolism and reversible contractile injury. Histologically, contraction bands, interstitial edema, mild inflammatory infiltrate and limited focal necrosis have been described, a picture different from ischemic transmural infarction. Contractile dysfunction therefore does not reflect massive myocyte loss, but myocardial stunning that can recover when adrenergic stress, edema and microvascular dysfunction subside.
A key point is the regional distribution of injury. In the classic form, the apical and mid-apical segments become hypokinetic, akinetic or dyskinetic, while the basal segments remain normal or hypercontractile. This topography has been linked to different density and sensitivity of beta-adrenergic receptors along the left ventricle. Under conditions of high adrenaline concentration, stimulation of beta-2 receptors may switch intracellular coupling from stimulatory G protein to inhibitory G protein, reducing contractility as a protective mechanism against catecholaminergic excess. The result is regional depression of contraction, especially in the most sensitive areas, while less affected regions may become hyperkinetic through compensation or residual adrenergic stimulation.
Coronary microvascular dysfunction contributes to the pathophysiology in a complex way. In many patients, abnormalities of coronary flow reserve, angiographic slow flow, microvascular vasoconstriction and perfusion defects have been observed. It is unclear whether microcirculation is the primary mechanism or a consequence of myocardial stunning, edema and extravascular compression exerted by dysfunctional segments. Both phenomena probably coexist: adrenergic discharge may induce microvascular vasoconstriction and endothelial injury, while edematous and contracturally altered myocardium may compress small intramural vessels, worsening local hypoperfusion without producing extensive ischemic necrosis as in persistent coronary occlusion.
Pathogenesis also includes myocardial and systemic inflammation. After the acute event, increased inflammatory mediators, myocardial edema on cardiac magnetic resonance (CMR) and persistent abnormalities of fine contractile function have been described even after normalization of left ventricular ejection fraction (LVEF). This is important because it explains why some patients continue to report dyspnea, fatigability, atypical chest pain or reduced exercise tolerance even when standard echocardiography appears recovered. Takotsubo is not always a completely resolved interlude: in some cases it leaves a biological convalescence phase longer than the simple recovery of macroscopic ventricular kinetics.
The hemodynamic pathophysiology depends on the pattern of ventricular involvement. In the apical variant, loss of contractility of the distal segments reduces stroke volume and increases filling pressures, with possible pulmonary congestion. Basal hyperkinesia may generate dynamic left ventricular outflow tract obstruction (LVOTO), especially in patients with a small ventricle, sigmoid septum, basal hypertrophy or hypovolemia. In this scenario, preload reduction, vasodilation and catecholaminergic inotropes may worsen the gradient, increase systolic mitral regurgitation caused by systolic anterior motion of the mitral valve and precipitate shock. Distinguishing shock due to pump failure from shock with LVOTO is therefore decisive, because hemodynamic treatment is opposite.
Takotsubo can also be induced or amplified by mechanical mechanisms. Some patients with ventricular hypertrophy, obstructive hypertrophic cardiomyopathy, sigmoid septum or small ventricular cavity may develop an abrupt intraventricular gradient during adrenergic activation, dehydration, exercise, anesthesia or physical stress. The gradient increases apical wall stress and may contribute to ballooning. This does not replace the neurocatecholaminergic theory, but broadens the model: in some patients, structural vulnerability of the ventricle makes it more likely that an adrenergic discharge will translate into segmental dysfunction.
The overall pathophysiological sequence can be summarized narratively: a predisposed subject undergoes an emotional, physical, neurological, endocrine or iatrogenic trigger; the trigger activates central stress circuits and the sympathetic system; the myocardium receives a disproportionate catecholaminergic and neuropeptidergic load; adrenergic receptors, microcirculation, endothelium, mitochondria and calcium homeostasis are perturbed; selectively vulnerable ventricular segments enter stunning; contraction becomes regionally heterogeneous; output may fall, filling pressures rise, the ventricle may develop dynamic gradients, edema, arrhythmias and thrombosis; finally, if the patient overcomes the acute phase, global function tends to recover within days or weeks, although symptoms and subclinical abnormalities may persist for longer.
The clinical presentation must be interpreted with the same urgency as an acute coronary syndrome, because at onset Takotsubo cannot be safely distinguished from acute myocardial infarction on symptoms alone. History-taking begins with reconstruction of the event chronology: time of onset, mode of onset, duration of symptoms, relationship with emotional or physical stress, possible hospital context, recent procedures, acute pain, infection, respiratory crisis, neurological event, catecholamine exposure, suspected pheochromocytoma, history of psychiatric or neurological disorders, previous similar episodes and traditional cardiovascular risk factors. This collection does not “diagnose” Takotsubo by itself, but it guides pre-test probability and helps recognize secondary or complicated forms.
The most frequent symptom is acute chest pain, often retrosternal, oppressive or constrictive, clinically overlapping with infarction pain. It may occur at rest, during stress or in the course of an acute disease. Dyspnea is the second cardinal symptom and may be mild, due to increased filling pressures, or severe, due to acute pulmonary edema. Palpitations, syncope, presyncope, nausea, vomiting, sweating, sudden asthenia and a sense of impending death may complete the picture. In some patients, especially elderly individuals or those hospitalized for neurological or internal diseases, onset may be atypical, with hypotension, desaturation, confusion, respiratory deterioration, arrhythmia or biomarker increase without evident chest pain.
The presence of an emotional trigger must not be overinterpreted. Chest pain after bereavement or fright may be Takotsubo, but it may also be an infarction favored by stress. Similarly, a patient without emotional stress may have Takotsubo after sepsis, epileptic seizure, surgery or respiratory exacerbation. In real clinical practice, the correct question is not whether the patient has had “a sorrow”, but whether in the preceding hours or days something occurred that was capable of activating the sympathetic system, increasing myocardial demand, altering vascular tone or producing endogenous or exogenous catecholamines.
During physical examination, the first assessment concerns hemodynamic stability, heart rate, blood pressure, oxygen saturation, temperature, level of consciousness, signs of peripheral hypoperfusion and signs of congestion. A stable patient may have an almost normal cardiopulmonary examination despite major abnormalities on electrocardiogram (ECG) and imaging. A complicated patient may present with tachycardia, hypotension, cold skin, oliguria, pulmonary crackles, third heart sound, jugular venous distension, systolic murmur due to mitral regurgitation or dynamic gradient, signs of pulmonary edema or cardiogenic shock. Physical examination must be repeated over time, because Takotsubo is dynamic: an initially stable picture may worsen in the first hours because of extension of stunning, development of LVOTO, arrhythmias or acute mitral regurgitation.
Chest pain and dyspnea arise from the interaction between regional systolic dysfunction, increased end-diastolic pressures, microvascular ischemia, myocardial edema and neurovegetative alterations. Syncope may depend on ventricular tachyarrhythmias, bradyarrhythmias, atrioventricular blocks, torsades de pointes, hypotension or shock. Palpitations may reflect adrenergic sinus tachycardia, atrial fibrillation, ventricular ectopy or ventricular tachycardias. Severe dyspnea indicates increased filling pressures and pulmonary congestion; if associated with hypotension, elevated lactate, oliguria or altered mental status, it must raise suspicion of shock.
Neurological manifestations may precede or accompany the syndrome. Epileptic seizures, focal deficits, sudden headache, meningeal signs, altered sensorium or coma point toward subarachnoid hemorrhage, stroke or another acute disease of the central nervous system. In these patients, Takotsubo may be secondary to the neurological lesion and present with ECG abnormalities, elevated troponin and ventricular dysfunction. The risk is attributing everything to infarction or, conversely, ignoring the heart because the neurological disease dominates the picture. Assessment must proceed in parallel, because cardiac injury may affect blood pressure, cerebral perfusion, oxygenation and neurological prognosis.
In patients with a physical trigger, presentation is often more severe than in purely emotional forms. Sepsis, respiratory failure, surgery, trauma and acute neurological diseases are associated with a higher risk of shock, arrhythmias, need for ventilation, multiorgan failure and mortality. This does not mean that the trigger “causes” a more aggressive form in all patients, but that Takotsubo occurs in an organism already subjected to a high inflammatory, catecholaminergic and metabolic load, with lower cardiopulmonary reserve and a higher probability of complications.
In men, Takotsubo is less frequent, but it is often more associated with physical triggers, severe comorbidities and a complicated course. In elderly women, the classic picture with chest pain after emotional stress is more recognizable, but this must not obscure the fact that concomitant diseases, coexisting coronary artery disease and non-apical forms are also frequent in this population. In young patients, endocrine, neurological, toxic, iatrogenic or rare genetic causes must be sought with particular attention, because the pre-test probability of spontaneous Takotsubo is lower than in postmenopausal women.
An important clinical element is the disproportion between symptoms, ECG, biomarkers and ventricular function. Many patients have elevated troponin, but the increase is often moderate compared with the extent of ventricular dysfunction observed on echocardiography or ventriculography. Conversely, B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) may be markedly increased, consistently with wall stress and acute ventricular failure. This dissociation is not pathognomonic, but it is a useful clue when integrated with imaging and coronary angiography.
Clinical assessment must always search for signs of complication. Worsening dyspnea, diffuse crackles, hypoxemia and need for oxygen suggest pulmonary edema. Hypotension, cold extremities, confusion and elevated lactate suggest shock. A new systolic murmur may indicate dynamic mitral regurgitation or, rarely, ventricular septal rupture. Persistent chest pain with instability may indicate concomitant infarction, aortic dissection, pulmonary embolism or mechanical complication. Acute neurological deficit after cardiac onset may indicate embolism from ventricular thrombus. Takotsubo should therefore not be observed as a “reassuring” diagnosis, but as an acute syndrome to be monitored until stabilization.
The diagnostic pathway begins as for every patient with acute chest pain, acute dyspnea, syncope or hemodynamic instability. The priority is to rapidly exclude an acute coronary syndrome with coronary occlusion, because delay in revascularization of ST-segment elevation acute myocardial infarction can be fatal. In the initial phase, it is not acceptable to assume Takotsubo only because the patient is an elderly woman, because she has experienced stress or because the picture “looks” like stress cardiomyopathy. ECG, troponin, hemodynamic assessment, echocardiography and invasive strategy must be used with an urgency-oriented logic.
The first level includes 12-lead ECG, continuous rhythm monitoring, serial measurement of cardiac troponin, complete blood count, electrolytes, creatinine, liver function tests, blood glucose, inflammatory markers, BNP or NT-proBNP, chest X-ray or lung ultrasound in the presence of dyspnea, blood gas analysis in unstable patients and echocardiographic assessment as soon as available. The ECG may show ST-segment elevation, ST-segment depression, T-wave inversion, transient Q waves, low voltage, corrected QT interval (QTc) prolongation or, rarely, absence of significant abnormalities. Electrocardiographic evolution is often dynamic: initial elevation may regress, negative T waves may become deep and diffuse, and QTc may lengthen in the subacute phase, increasing the risk of torsades de pointes.
Transthoracic echocardiography is central because it shows the hemodynamic phenotype of the syndrome. It must assess LVEF, distribution of wall motion abnormalities, presence of apical ballooning, mid-ventricular variant, basal variant or focal form, right ventricular involvement, mitral regurgitation, estimated pulmonary pressure, pericardial effusion, presence of apical thrombus and possible LVOTO. The typical finding is regional dysfunction that often extends beyond the territory of a single epicardial coronary artery, but focal forms exist and can mimic a segmental coronary lesion. For this reason, echocardiography strongly guides the diagnosis, but does not replace coronary assessment when the clinical picture requires invasive exclusion of infarction.
Urgent coronary angiography is indicated in patients with ST-segment elevation, hemodynamic instability, severe arrhythmias, high probability of infarction or a picture that cannot be deferred. It allows exclusion of a responsible coronary occlusion, assessment of concomitant coronary artery disease and, if performed together with ventriculography, direct documentation of the ballooning pattern. The presence of significant coronary artery disease does not exclude Takotsubo: a patient may have stable coronary stenoses and Takotsubo, or Takotsubo may coexist with a coronary lesion that is not responsible for the extent of dysfunction. The diagnostic point is therefore not the absolute absence of plaques, but the absence of a culprit lesion capable of fully explaining the distribution of ventricular dysfunction and the clinical picture.
In patients without ST-segment elevation and clinically stable, the InterTAK Diagnostic Score can help estimate the probability of Takotsubo before definitive imaging. The score considers female sex, emotional trigger, physical trigger, absence of ST-segment depression except in aVR, psychiatric disorders, neurological disorders and QTc prolongation. A high score increases the probability of Takotsubo, but it does not replace clinical judgment, does not eliminate the need to exclude infarction when indicated and does not confirm the diagnosis by itself. It is an initial stratification tool, particularly useful in comparison with non-ST-segment elevation acute coronary syndrome.
The most widely used international diagnostic criteria are the InterTAK Diagnostic Criteria. They should be interpreted as an integrated framework and not as a mechanical checklist isolated from the clinical context. Their usefulness lies in having overcome some limitations of older criteria, particularly the absolute exclusion of coronary artery disease and pheochromocytoma, which today are no longer considered incompatible with the diagnosis.
InterTAK Diagnostic Criteria
CMR is the most important second-level examination for confirming reversible myocardial injury and distinguishing Takotsubo from myocarditis and infarction. The characteristic finding is myocardial edema in the dysfunctional regions, documented with T2-weighted sequences and T2 mapping, in the absence of an ischemic pattern of transmural or subendocardial necrosis consistent with a coronary territory. The absence of significant late gadolinium enhancement (LGE) has traditionally been considered an element in favor of Takotsubo, but more recent literature has clarified that mild or transient LGE findings may be observed in some patients, especially if the examination is very early or if edema is marked. For this reason, CMR should not be interpreted with an absolute rule of “absent LGE equals Takotsubo, present LGE equals another diagnosis”, but according to site, intensity, distribution, timing, edema, kinetics and follow-up.
The diagnosis becomes more robust when recovery of ventricular function is demonstrated. In most patients, LVEF and regional abnormalities improve substantially within days or weeks, with recovery often complete within one to three months. However, documented recovery is not always available in fatal cases, in patients lost to follow-up or in cases with severe comorbidities. Persistence of focal dysfunction, dilation, scar with an incompatible pattern or progressive worsening must prompt reconsideration of alternative diagnoses, including unrecognized infarction, myocarditis, inflammatory cardiomyopathy, ischemic cardiomyopathy, arrhythmic cardiomyopathy, tachycardiomyopathy and infiltrative cardiomyopathies.
The main differential diagnosis is acute myocardial infarction. Infarction is sustained by occlusion or plaque instability, produces ischemic necrosis in a vascular territory and requires specific coronary treatment. Takotsubo produces reversible dysfunction often wider than the coronary territory, with relatively less marked troponin elevation compared with dysfunction and more marked BNP or NT-proBNP increase. However, none of these elements alone is sufficient. Infarction may also occur after stress, Takotsubo may also have ST-segment elevation, and coronary artery disease may coexist with Takotsubo. Coronary angiography, ventricular imaging and CMR are therefore the core of the distinction.
Acute myocarditis is the other crucial diagnosis. It may cause chest pain, elevated troponin, ECG abnormalities, ventricular dysfunction and non-obstructed coronaries. CMR helps because myocarditis typically shows edema and non-ischemic LGE, often subepicardial or mid-wall, with a distribution different from ballooning. Fever, viral syndrome, marked increase in inflammatory markers, pericardial effusion, arrhythmias and CMR pattern point toward myocarditis. In selected cases, especially when there is instability, severe arrhythmias, suspicion of fulminant myocarditis or persistent diagnostic uncertainty, endomyocardial biopsy may be considered according to specialist indication.
Pulmonary embolism, aortic dissection, hypertensive crisis, sepsis with septic cardiomyopathy, tachycardiomyopathy, multivessel coronary spasm, primary microvascular dysfunction, intoxications, thyrotoxicosis, adrenal crisis, pheochromocytoma and myocardial injury from exogenous catecholamines must also be excluded. Pulmonary embolism may cause dyspnea, pain, elevated troponin and right ventricular dysfunction; aortic dissection may mimic coronary pain and cause secondary ischemia; pheochromocytoma should be suspected in the presence of hypertensive crises, headache, sweating, paroxysmal palpitations or recurrent Takotsubo without explanation. Diagnosis is therefore not limited to the heart: it must include a rational search for the trigger, especially in patients with atypical presentation, recurrence, young age or unexplained instability.
Once the diagnosis has been made, investigations also serve to define risk and target organs. Serial echocardiograms evaluate recovery, LVOTO, mitral regurgitation, ventricular thrombus, pulmonary pressure and right ventricular function. Rhythm monitoring detects atrial fibrillation, ventricular tachycardia, torsades de pointes, bradycardia and atrioventricular blocks. Electrolytes, especially potassium and magnesium, should be corrected to reduce arrhythmic risk. CMR may be repeated if dysfunction persists or if the first examination was ambiguous. In patients with neurological, oncological, endocrine or infectious triggers, defining the precipitating disease is an integral part of management because it affects prognosis and recurrence risk.
The treatment of Takotsubo cardiomyopathy is based on an initial principle: until acute myocardial infarction has been excluded, the patient must be managed as an acute coronary syndrome. This means urgent assessment, monitoring, access to the catheterization laboratory when indicated, pain control, treatment of instability and prevention of arrhythmias. Only after exclusion of the responsible coronary lesion and definition of the ventricular pattern is therapy redirected toward Takotsubo. There are no large randomized trials defining a universal specific therapy; many strategies derive from expert consensus, observational registries, pathophysiology and treatment of complications.
In the stable patient, without shock, without severe pulmonary edema, without significant LVOTO and without ventricular thrombus, management is mainly supportive. Rest, telemetry monitoring, electrolyte correction, discontinuation of medications that prolong QT when possible, treatment of pain, control of clinically significant anxiety and treatment of the precipitating trigger are used. If LVEF is reduced and there are no contraindications, angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) may be used, with the aim of supporting favorable remodeling during the recovery phase. Beta-blockers are often used to reduce adrenergic tone, heart rate and dynamic gradient when present, but their ability to prevent recurrence has not been definitively demonstrated.
Acute heart failure without LVOTO is treated according to hemodynamic physiology: oxygen if hypoxemia is present, diuretics if congestion is present, vasodilators only if blood pressure is adequate and dynamic obstruction is absent, non-invasive or invasive ventilation if respiratory failure is present. Catecholaminergic inotropes must be used with extreme caution, because the pathogenetic mechanism of Takotsubo is linked precisely to adrenergic excess. In low-output cases without LVOTO, when inotropic or vasopressor support is needed, the choice must be individualized in an intensive care setting. In refractory cases, mechanical circulatory support may be preferable to prolonged catecholaminergic escalation.
The presence of LVOTO radically changes treatment. In this situation, diuretics, nitrates, vasodilators and preload reduction may worsen the gradient, while beta-adrenergic inotropes may increase basal hyperkinesia and worsen obstruction. Treatment tends to favor cautious volume expansion if pulmonary congestion is absent, short-acting beta-blockade in patients with sufficient blood pressure, correction of hypovolemia, discontinuation of vasodilators and close echocardiographic reassessment. If LVOTO and shock coexist, management is complex and must take place in a cardiac intensive care unit, because therapy useful for pump failure may be harmful for dynamic obstruction.
Cardiogenic shock is one of the most important complications and requires immediate distinction between shock due to global or extensive systolic dysfunction, shock due to LVOTO, shock due to acute mitral regurgitation, shock due to right ventricular involvement and mixed shock with sepsis or respiratory failure. Serial echocardiography, invasive hemodynamics in selected cases and assessment of systemic perfusion guide therapy. In patients with refractory shock, mechanical circulatory support devices may be considered, including intra-aortic balloon pump in selected settings, percutaneous ventricular assist devices or venoarterial extracorporeal membrane oxygenation (VA-ECMO), taking into account the presence of LVOTO, right ventricular function, oxygenation and the risk of vascular complications.
Prevention of ventricular thrombosis is relevant especially in extensive apical forms, with severe akinesia, markedly reduced LVEF and elevated troponin. If a left ventricular thrombus is documented, anticoagulation is indicated in the absence of contraindications, generally until thrombus resolution and recovery of kinetics. In high-risk patients without visible thrombus, the decision to anticoagulate is individual and must balance embolic risk and bleeding risk. Contrast echocardiography or CMR may be useful when suspicion of apical thrombus is high and the echocardiographic window is suboptimal.
Arrhythmias require specific management. QTc prolongation requires aggressive correction of hypokalemia and hypomagnesemia, discontinuation of QT-prolonging medications when possible and continuous monitoring. Torsades de pointes is treated according to emergency principles, with intravenous magnesium, correction of precipitating factors, increase in heart rate in bradycardia-dependent cases and defibrillation if degeneration into ventricular fibrillation or instability occurs. Sustained ventricular tachycardias, severe bradyarrhythmias and atrioventricular blocks must be treated in a monitored setting. Early implantation of a permanent defibrillator is not automatic, because many arrhythmias are linked to the transient phase of edema, long QT and acute dysfunction; the decision requires reassessment after recovery and distinction from underlying arrhythmogenic heart diseases.
Treatment of the trigger is part of causal therapy. An epileptic seizure must be controlled, sepsis must be treated rapidly, respiratory failure must be corrected, severe pain must be sedated appropriately, an acute neurological disease must be managed in a dedicated setting, pheochromocytoma must be recognized and treated through an endocrine-cardiac surgical pathway, and catecholaminergic iatrogenesis must be remodulated. If the trigger persists, the myocardium remains exposed to the stimulus that produced dysfunction and recovery may be delayed or complicated.
After discharge, follow-up must document recovery of ventricular function, resolution of any thrombus, normalization or improvement of QTc, regression of symptoms and control of comorbidities. An echocardiogram at four to six weeks and a further check within three to six months are often reasonable, modulating timing according to severity, LVEF, complications and persistence of symptoms. CMR is useful if recovery is incomplete, if the diagnosis remains uncertain, if myocarditis is suspected or if structural abnormalities persist. In patients with anxiety, depression, post-traumatic stress disorder, pathological bereavement or relevant emotional triggers, psychological or psychiatric assessment may have clinical value, not because the disease is “psychosomatic”, but because the autonomic system, stress response and quality of life are part of overall vulnerability.
Immediate prognosis depends on age, male sex, physical trigger, acute neurological disease, malignancy, shock, low LVEF, right ventricular involvement, significant LVOTO, mitral regurgitation, arrhythmias, respiratory failure, renal failure and systemic comorbidities. Most patients recover ventricular function, but registries have demonstrated non-negligible rates of in-hospital complications and mortality, sometimes comparable to those observed in acute coronary syndromes in specific populations. The word “reversible” must therefore not be confused with “harmless”.
Long-term prognosis is heterogeneous. Some patients remain asymptomatic after complete recovery; others have fatigue, dyspnea, chest pain, reduced functional capacity, altered cardiac energy metabolism, residual inflammation or subclinical dysfunction documented by advanced methods. Recurrence is possible, even years later, and may recur with the same pattern or with a different pattern. No pharmacological therapy has definitively demonstrated that it abolishes recurrence risk. The most rational strategy is to identify and treat predisposing factors, avoid unnecessary catecholaminergic exposures, control comorbidities, schedule cardiological follow-up and provide the patient with clear instructions on recognizing new acute symptoms.
The complications of Takotsubo cardiomyopathy derive from acute ventricular dysfunction, heterogeneous contraction, myocardial edema, electrical instability, neurovegetative activation and the clinical context that precipitated the event. Their frequency varies according to the population studied: emergency department patients with an isolated emotional trigger generally have a less complex course than patients admitted to intensive care for sepsis, stroke, subarachnoid hemorrhage, major surgery or respiratory failure. The systematic search for complications must therefore begin at diagnosis and continue until ventricular function has recovered.
Acute heart failure is the most frequent complication. It occurs because the affected ventricular segments lose contractility, stroke volume decreases, filling pressures increase and blood backs up upstream of the left ventricle. Clinically, it may manifest with dyspnea, orthopnea, crackles, hypoxemia, pulmonary edema and need for ventilation. The risk increases when LVEF is severely reduced, when involvement affects a large portion of the left ventricle, when mitral regurgitation is present or when the patient has reduced pulmonary reserve.
Cardiogenic shock is the most feared hemodynamic complication. It may result from pump failure due to extensive ventricular akinesia, LVOTO, right ventricular involvement, severe mitral regurgitation, arrhythmias or combination with sepsis and vasoplegia. Differentiating the mechanism is essential because therapy changes: in pump-failure shock, circulatory support and intensive heart failure therapy may be needed, whereas in shock with LVOTO, preload reduction and inotropic stimulation may be harmful. Shock is associated with higher early and late mortality and identifies a biologically more severe disease phenotype.
LVOTO is a complication and, in some cases, a possible pathogenetic amplifier. It arises from hyperkinesia of the basal segments and dynamic narrowing of the outflow tract, often favored by small ventricular cavity, basal septal hypertrophy, hypovolemia and elevated adrenergic tone. It may be associated with systolic anterior motion of the mitral valve and mitral regurgitation. The patient may worsen after nitrates, diuretics, vasodilators or inotropes, because these interventions reduce ventricular volume or increase basal contractile force, accentuating the gradient.
Acute mitral regurgitation may occur through two main mechanisms. In the first, geometric distortion of the ventricle and dysfunction of the papillary muscles reduce leaflet coaptation. In the second, LVOTO induces systolic anterior motion of the mitral valve, with dynamic regurgitation. In both cases, regurgitation increases the volume that refluxes into the left atrium, worsens pulmonary congestion and may contribute to shock. Its severity must be reassessed after recovery, because it often regresses together with normalization of ventricular kinetics.
Right ventricular involvement identifies a more extensive form. It may cause hypotension, increased systemic venous pressures, jugular venous distension, hepatic congestion, worsening tolerance to fluids and greater difficulty in hemodynamic management. If respiratory failure or pulmonary embolism coexists, differential diagnosis becomes more complex. Echocardiography must therefore always assess the right ventricle as well, not only the pattern of the left ventricle.
Arrhythmias are favored by myocardial edema, dispersion of repolarization, QTc prolongation, sympathetic hyperactivation, electrolyte imbalances and ventricular dysfunction. Atrial fibrillation, supraventricular tachycardias, ventricular ectopy, ventricular tachycardia, torsades de pointes, ventricular fibrillation, sinus bradycardia and atrioventricular blocks may occur. Life-threatening ventricular arrhythmias are more likely in the acute and subacute phase, when QTc is long and the myocardium is edematous. Prevention relies on monitoring, correction of potassium and magnesium, avoidance of medications that prolong QT and treatment of significant bradycardia when it favors torsades de pointes.
Left ventricular thrombosis derives from blood stasis in akinetic or dyskinetic segments, especially at the apex during extensive apical ballooning. The thrombus may embolize, causing ischemic stroke, peripheral ischemia or systemic emboli. The risk increases when LVEF is severely reduced, apical akinesia is extensive and persistent, and troponin is elevated. Since the thrombus may not be evident at the first assessment, imaging must be repeated in high-risk patients, especially if echocardiographic quality is limited or if neurological signs appear.
Mechanical complications are rare but severe. Free wall rupture, ventricular septal defect and rupture or severe dysfunction of the mitral apparatus are much less frequent than in transmural infarction, because extensive necrosis is not the dominant mechanism in Takotsubo. However, they may occur, especially in the presence of elevated intraventricular pressures, LVOTO, severe myocardial injury or delayed diagnosis. Sudden pain, hemodynamic collapse, tamponade, new murmur or rapid deterioration must raise suspicion of a mechanical complication and require urgent imaging.
Acute pulmonary edema and respiratory failure may be direct consequences of increased filling pressures, but they may also reflect the trigger that caused Takotsubo, such as pneumonia, sepsis, pulmonary embolism or asthma attack. This overlap is frequent in critically ill patients: the heart worsens the lung and the lung worsens the heart through hypoxia, acidosis, increased sympathetic tone and increased right ventricular afterload. Management must therefore integrate intensive cardiology and respiratory treatment.
Recurrences are a late complication. They may occur after months or years, with a similar or different trigger, and with a ventricular pattern not necessarily identical to the first episode. Recurrence suggests persistent vulnerability of the neurocardiac axis or the presence of a trigger that has not been eliminated, such as neurological disorder, pheochromocytoma, iatrogenic exposure, uncontrolled psychiatric disease or structural predisposition to intraventricular gradients. After a recurrence, it is particularly important to review differential diagnoses, triggers, medications, comorbidities and the quality of previous recovery.
Persistence of symptoms after apparent recovery is an underestimated complication. Some patients report exertional dyspnea, reduced functional capacity, intermittent chest pain, palpitations, profound fatigue or reduced quality of life despite normal LVEF. Possible explanations include abnormalities in myocardial deformation, residual microvascular dysfunction, prolonged edema, inflammation, energetic alterations, deconditioning, post-event anxiety and non-cardiac comorbidities. This phenomenon requires avoiding an overly rapid conceptual discharge: echocardiographic recovery does not always coincide with complete biological and functional recovery.
Mortality may be cardiovascular or non-cardiovascular. Cardiovascular causes include shock, heart failure, arrhythmias, embolism, mechanical complications and recurrence. Non-cardiovascular causes often reflect the physical trigger or comorbidity, such as sepsis, malignancy, neurological disease or respiratory failure. This explains why the prognosis of Takotsubo does not depend only on the shape of the ventricle, but also on the context in which the syndrome appears. Takotsubo after bereavement in an otherwise stable patient and Takotsubo during subarachnoid hemorrhage or sepsis do not have the same prognostic meaning, even if the ventricular pattern may look similar.